Ex-Novartis Exec Rahman To Steer Clinical Sciences At Glenmark
Dr. Mahboob Rahman, a former Novartis therapeutic area head for immunology in global clinical development, joins Glenmark at a key juncture as the Indian firm advances several key R&D assets including in immuno-oncology. “Portfolio prioritization” and bringing in the right talent rank high on Rahman’s immediate agenda, while a “fast-paced” environment appears to be among the key draws for his move.
You may also be interested in...
Glenmark has sealed a licensing deal for its early stage immuno-oncology asset with China’s Harbour BioMed, opening up new possibilities around collaborations between the two Asian nations. The Indian firm appears upbeat about the prospects of building further on this new linkage.
With a basket of interesting R&D assets in hand, India’s Glenmark says it is pursuing regional out-licensing deals, including in Japan and China, for some of its molecules. Expectations are also running high on the firm’s first US NDA submission for seasonal allergic rhinitis.
Boehringer Ingelheim’s Country Managing Director for India Vani Manja outlines how she expects to shape the German group’s growth trajectory in the country, while also dealing with the unexpected pre-expiry challenge to the Jardiance patent. The executive also discusses her personal career journey, learnings from her prior role in the US and gives advice to women executives seeking to move up to the higher echelons of the corporate world.